Randomized phase II study of S-1/CDDP plus TSU-68 versus S-1/CDDP in patients with advanced gastric cancer.
Kensei Yamaguchi
No relevant relationships to disclose
Wasaburo Koizumi
Other Remuneration - Taiho Pharmaceutical
Hisashi Hosaka
No relevant relationships to disclose
Yasutaka Takinishi
No relevant relationships to disclose
Norisuke Nakayama
No relevant relationships to disclose
Takuo Hara
No relevant relationships to disclose
Kei Muro
Consultant or Advisory Role - Novartis; Ono Pharmaceutical
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - AstraZeneca; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Merck Serono; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Hideo Baba
Research Funding - Taiho Pharmaceutical
Yasutsuna Sasaki
Research Funding - Taiho Pharmaceutical
Tomohiro Nishina
No relevant relationships to disclose
Nozomu Fuse
Honoraria - Chugai Pharma; Novartis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bayer; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Taito Esaki
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca; Taiho Pharmaceutical; Yakult Honsha
Masakazu Takagi
No relevant relationships to disclose
Masahiro Gotoh
No relevant relationships to disclose
Ryuichi Kitamura
Employment or Leadership Position - Taiho Pharmaceutical
Hideki Matsumoto
Employment or Leadership Position - Taiho Pharmaceutical
Stock Ownership - Taiho Pharmaceutical
Tsuneo Sasaki
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical